EPS for Aeterna Zentaris Inc. (AEZS) Expected At $-0.32

July 13, 2018 - By Mary Markley

Analysts expect Aeterna Zentaris Inc. (NASDAQ:AEZS) to report $-0.32 EPS on August, 9.They anticipate $0.14 EPS change or 30.43 % from last quarter’s $-0.46 EPS. After having $0.87 EPS previously, Aeterna Zentaris Inc.’s analysts see -136.78 % EPS growth. It closed at $1.96 lastly. It is down 125.00% since July 14, 2017 and is uptrending. It has outperformed by 112.43% the S&P500.

Aeterna Zentaris Inc. (NASDAQ:AEZS) Ratings Coverage

Among 2 analysts covering Aeterna Zentaris (NASDAQ:AEZS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aeterna Zentaris had 3 analyst reports since March 29, 2018 according to SRatingsIntel. H.C. Wainwright maintained the shares of AEZS in report on Wednesday, May 9 with “Buy” rating. The stock of Aeterna Zentaris Inc. (NASDAQ:AEZS) has “Buy” rating given on Thursday, March 29 by H.C. Wainwright.

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women's health. The company has market cap of $31.98 million. The company's product pipeline includes Zoptrex, which completed Phase III clinical study for women with advanced, recurrent, or metastatic endometrial cancer, as well as in various phases for the treatment of ovarian and prostate cancer; and MACRILEN, which completed Phase III trial for use in the diagnosis of adult growth hormone deficiency. It has a 18.85 P/E ratio. It is also developing an LHRH-disorazol Z conjugate, which is in pre-clinical development in oncology.

More news for Aeterna Zentaris Inc. (NASDAQ:AEZS) were recently published by: Seekingalpha.com, which released: “Key events next week – healthcare” on June 15, 2018. Benzinga.com‘s article titled: “30 Stocks Moving In Thursday’s Pre-Market Session” and published on June 21, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.